The Molecular Oncology Resource is an essential component of our JHU ICMIC as it will provide: (i) a centralized resource for production of reagents and constructs, as well as expertise in molecular biology, (ii) a centralized resource for human cancer cell lines including cell lines constructed to report on hypoxia or with knockdown or overexpression of molecular pathways, (iii) clinical specimens to study in the research projects, (iv) expertise and guidance in immunostaining, molecular pathology characterization of archived or biopsied clinical and preclinical tissues obtained in the research components, (v) veterinary expertise and guidance for the vertebrate animal studies, and (vi) expert guidance in clinical translation. Experts in integrating molecular biology for molecular imaging (Dr. Raman, co-director), molecular biology (Dr. Sukumar), lentiviral vectors (Dr. Krishnamachary), vertebrate animal pathology and veterinary expertise (Dr. Gabrielson), pathology (Dr. Argani), and clinical translation (Dr. Jaffee) will form this resource. They will work closely with the JHU ICMIC investigators in experimental design and implementation of preclinical studies, use of human tissues and interpretation of data obtained using human tissues, molecular characterization of cells and tumor tissue, and the creation of novel reagents and constructs to advance the goals of the JHU ICMIC Program. We have restructured this resource to include Dr. Elizabeth Jaffee, the Associate Director for Translational Research at the Sidney Kimmel Cancer Center at Johns Hopkins. As Co-Director of this resource. Dr. Jaffee will provide expertise and guidance in clinical translation studies. This resource will provide the necessary infrastructure and support for molecular biology, pathology, and translational oncology for the four research components, the current and future developmental projects, and the research project of each career development trainee.
The Molecular Oncology Resource will provide the infrastructure for JHU ICMIC studies that require expertise and assistance in molecular biology, pathology, veterinary medicine, and clinical translation.
|Penet, Marie-France; Shah, Tariq; Bharti, Santosh et al. (2015) Metabolic imaging of pancreatic ductal adenocarcinoma detects altered choline metabolism. Clin Cancer Res 21:386-95|
|Ahn, Eun Hyun; Kim, Younghoon; Kshitiz et al. (2014) Spatial control of adult stem cell fate using nanotopographic cues. Biomaterials 35:2401-10|
|El Khouli, Riham H; Macura, Katarzyna J; Kamel, Ihab R et al. (2014) The effects of applying breast compression in dynamic contrast material-enhanced MR imaging. Radiology 272:79-90|
|Nimmagadda, Sridhar; Pullambhatla, Mrudula; Lisok, Ala et al. (2014) Imaging Axl expression in pancreatic and prostate cancer xenografts. Biochem Biophys Res Commun 443:635-40|
|Yadav, Nirbhay N; Xu, Jiadi; Bar-Shir, Amnon et al. (2014) Natural D-glucose as a biodegradable MRI relaxation agent. Magn Reson Med 72:823-8|
|Gadiya, Mayur; Mori, Noriko; Cao, Maria D et al. (2014) Phospholipase D1 and choline kinase-? are interactive targets in breast cancer. Cancer Biol Ther 15:593-601|
|Shamir, Eliah R; Pappalardo, Elisa; Jorgens, Danielle M et al. (2014) Twist1-induced dissemination preserves epithelial identity and requires E-cadherin. J Cell Biol 204:839-56|
|Huang, Peng; Ou, Ai-hua; Piantadosi, Steven et al. (2014) Formulating appropriate statistical hypotheses for treatment comparison in clinical trial design and analysis. Contemp Clin Trials 39:294-302|
|Subhawong, Ty K; Jacobs, Michael A; Fayad, Laura M (2014) Insights into quantitative diffusion-weighted MRI for musculoskeletal tumor imaging. AJR Am J Roentgenol 203:560-72|
|Zhu, Wenlian; Kato, Yoshinori; Artemov, Dmitri (2014) Water exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters: effect of bevacizumab/paclitaxel combination therapy. MAGMA 27:161-70|
Showing the most recent 10 out of 142 publications